Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte, Inc. (Nasdaq: VCYT) will release its financial results for Q4 and full-year 2021 after market close on February 28, 2022. A conference call is scheduled at 4:30 p.m. ET to discuss these results and provide a general business update. Investors can access the conference call via the company's website, where a replay will also be available afterward. Veracyte is a diagnostics company focused on improving patient care through genomic tests for various cancers and diseases, leveraging advanced technology to expedite diagnosis and treatment.
Veracyte, Inc. (Nasdaq: VCYT) presented new data at the 2022 ASCO GU Symposium confirming the efficacy of the Decipher Prostate Genomic Classifier for prostate cancer treatment selection. This Phase 3 study validates the Classifier's role as a prognostic biomarker for men with intermediate-risk prostate cancer, providing critical insights for personalized treatment. Key findings indicate that patients classified as Decipher ‘high-risk’ have significantly worse clinical outcomes compared to ‘low-risk’ patients. This innovative approach could greatly enhance treatment strategies for prostate cancer patients.
Veracyte (Nasdaq: VCYT) announced that CEO Marc Stapley and CFO Rebecca Chambers will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 2:20 p.m. Eastern Time. A live audio webcast of the presentation will be available on Veracyte’s website, with a replay accessible for 90 days afterward. Veracyte specializes in diagnostics, offering tests for various cancers and other diseases, utilizing genomic advancements to enhance patient care.
Veracyte (NASDAQ: VCYT) announced the presentation of six abstracts at the 2022 ASCO GU Cancers Symposium, occurring from February 17-19, 2022. The studies focus on the Decipher genomic classifier as a prognostic biomarker for intermediate-risk prostate cancer, marking a significant late-stage validation of gene expression classifiers. The presentations will share insights on risk stratification and treatment guidance for urologic cancers.
The event takes place in location value="LU/us.ca.sanfrn"San Francisco, Calif..
Summary not available.
Veracyte (NASDAQ: VCYT) has announced significant leadership promotions aimed at enhancing its strategic vision in diagnostics. Tina Nova, Ph.D., is appointed president of the CLIA U.S. business, while Stephane Debono becomes general manager for IVD and EMEA organizations. Giulia C. Kennedy, Ph.D., is named global chief scientific officer and chief medical officer. These appointments are expected to align Veracyte's operations and bolster its market presence. The company focuses on developing innovative diagnostic tests to address unmet clinical needs, ultimately improving patient outcomes globally.
Veracyte, Inc. (NASDAQ: VCYT) released clinical data supporting the Envisia Genomic Classifier's role in enhancing diagnostic and treatment processes for patients with idiopathic pulmonary fibrosis (IPF). The findings, published in the Annals of the American Thoracic Society, demonstrate a significant increase in IPF diagnoses (39%) and physician confidence (36.2%) post-Envisia application. The study emphasizes reduced reliance on invasive procedures while promoting timely treatment recommendations, with potential benefits for approximately 200,000 patients annually in the U.S. and Europe.
Veracyte, Inc. (NASDAQ: VCYT) announced the Swedish Medical Technologies Product Council's recommendation for the Prosigna Breast Cancer Assay, enabling immediate reimbursement across all Swedish healthcare regions as of November 22, 2021. This marks a significant advancement following its prior approval in Germany, solidifying Prosigna's reimbursement momentum in the EU. The assay aids in chemotherapy decisions for women over 50 with specific breast cancer types, ensuring access without legal restrictions.
Veracyte (NASDAQ: VCYT) announced new data from three posters presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, showcasing the potential of Brightplex technology in immuno-oncology. This technology assesses the tumor micro-environment and aids in designing effective immunotherapies. Notably, findings from the PIONeeR project suggest that the Brightplex TCE assay can stratify non-small cell lung cancer patients into four subtypes, potentially predicting outcomes based on T-cell densities. This innovation positions Veracyte favorably in advancing cancer treatment.
Veracyte reported a 94% increase in total revenue to $60.4 million for Q3 2021, aided by its HalioDx acquisition. The company launched its innovative Percepta Nasal Swab and Decipher Bladder genomic tests amidst COVID-19 challenges. Despite growing revenues, Veracyte's operating expenses surged 123%, leading to a net loss of $14.1 million, a 243% increase year-over-year. The updated 2021 revenue guidance ranges from $210 million to $218 million, projecting 79% to 86% growth compared to 2020.